R. Krauss

Phase I study of domatinostat (4SC‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

M. Schwab, R. Bartz, W. Aulitzky, 2019, European journal of haematology.

The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models

A. Villanueva, M. Segura, R. Noguera, 2021, Clinical and translational medicine.

A Novel Microtubule Inhibitor 4SC-207 with Anti-Proliferative Activity in Taxane-Resistant Cells

R. Baumgartner, S. Hamm, H. Kohlhof, 2013, PloS one.

[Clinical and experimental studies on butazolidine effects and its application in leukemias, neoplastic processes and lymphogranulomatosis].

L. Heilmeyer, H. Harwerth, R. Krauss, 1953, Arzneimittel-Forschung.

First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).

R. Baumgartner, W. Aulitzky, A. Engert, 2014 .